Demand your doctor see if you need something like this if you are immobile. Who the hell is going to research this for stroke other than a great stroke association?
http://uk.reuters.com/article/2013/12/06/us-novartis-musclewasting-drug-idUKBRE9B50KF20131206
It is betting that the drug, known as
bimagrumab or BYM338 and developed with German biotech company
MorphoSys, might help combat muscle loss associated with conditions like
cancer and chronic lung disease that affect millions of people.
It
could even be beneficial for patients recovering from injury or an
operation, and the drugmaker is currently conducting a Phase II trial
for hip fracture recovery.
Novartis
is not the only pharmaceutical firm working on muscle-building
treatments. But it is heading the field in sIBM with BYM338, which was
granted breakthrough therapy status from U.S. health regulators in
August and is entering late-stage trials. It expects to file for
approval in 2016.
Eli
Lily is coming up close behind with two mid-stage studies for its drug
LY2495655 as a treatment for muscle weakness and muscular atrophy.
Meanwhile,
Regeneron and Sanofi have a drug in early stage development as a
treatment for sarcopenia, the muscle loss associated with aging.
More at link.
No comments:
Post a Comment